Experience

23andMe

• United States
• Biotechnology Research
• 400 - 500 Employee

• Scientist II

  • May 2019 - Present

  South San Francisco



Bayer

• Chemical Manufacturing
• 700 & Above Employee

• Staff Scientist

  • Jun 2012 - May 2019

  San Francisco Bay Area • Developed and validated bioanalytical assays for quantitative detection of various protein drug modalities (whole antibody, antibody fragments, bispecific antibody, protein-Fc fusion, antibody-drug conjugate) in biological matrices (plasma, tumor, eyes, red blood cells) following FDA bioanalytical guideline. • Implemented in-house developed assays to support preclinical in vivo PK, PD/PK, TK studies for various disease indications in animal models, interpreted data, and generated and… Show more • Developed and validated bioanalytical assays for quantitative detection of various protein drug modalities (whole antibody, antibody fragments, bispecific antibody, protein-Fc fusion, antibody-drug conjugate) in biological matrices (plasma, tumor, eyes, red blood cells) following FDA bioanalytical guideline. • Implemented in-house developed assays to support preclinical in vivo PK, PD/PK, TK studies for various disease indications in animal models, interpreted data, and generated and delivered reports. • Evaluated immunogenicity of antibody therapeutics with aberrant PK profiles developing ADA detection assays. • Developed and validated wash free homogeneous assays as alternatives to conventional ELISAs to improve bioanalytical workflows. • Developed and validated assays enabling identification of antibodies with potential PK risk at early lead discovery and adapted as standard screening methods. • Led bioanalytical project in exploring emerging bioanalytical technologies and established Gyros system as one of major bioanalytical platforms. • Created pharma reports for lead molecules internally approved for clinical trials and transferred assays to responsible teams. • Contributed to cross functional project teams as a key member providing ideas, suggestions, and experimental data. • Proposed and led project in discovering nanobody therapeutics for eye disease, investigating target identification, and conducting FTO analysis and budget evaluation. • Evaluated performance of bioanalytical CRO conducting parallel analysis of internally prepared samples to find outsourcing partner. Show less



University of California, Davis

• United States
• Higher Education
• 700 & Above Employee

• Assistant Project Scientist

  • Jan 2009 - Mar 2012

  • Isolated recombinant alpaca heavy chain single domain antibodies derived from laboratory-constructed phage alpaca antibody libraries and developed robust immunoassays for small compound and protein. • Developed innovative non-competitive phage anti-immune complex assay (PHAIA) for small molecules with enhanced sensitivity and specificity utilizing phage-displayed peptides that recognize conformational change of antibody induced by antibody-target analyte binding. • Expanded the scope… Show more • Isolated recombinant alpaca heavy chain single domain antibodies derived from laboratory-constructed phage alpaca antibody libraries and developed robust immunoassays for small compound and protein. • Developed innovative non-competitive phage anti-immune complex assay (PHAIA) for small molecules with enhanced sensitivity and specificity utilizing phage-displayed peptides that recognize conformational change of antibody induced by antibody-target analyte binding. • Expanded the scope of PHAIA technology, by developing various novel immunoassay formats. • Developed ultra sensitive biosensors for the detection of IgG, a breast cancer biomarker, and a food toxin performing immunoassays on a photonic crystal nano-well array chip devised by UCD engineers. • Successfully partnered with three small business entities to write funded SBIR and STTR grants serving as university or contact principal investigator. • Supervised four international visiting scholars, two postdocs, and four undergraduate students.

• Postdoctoral researcher

  • Jan 2005 - Jun 2009

  • Developed immunoassay for human urinary biomarker of pyrethroid insecticides at sub ppb level. • Conducted analysis of hundreds of urine samples collected from forest workers to assess human exposure to pyrethroid insecticides using laboratory-developed immunoassay. • Developed novel heterologous competitive immunoassays applying phage-displayed peptide mimotopes as substitutes for chemical competing haptens.



University of Hawaii at Manoa

• United States
• Higher Education
• 700 & Above Employee

• Graduate Research Assistant

  • Aug 1999 - Dec 2003

  • Developed sensitive immunoassays for quantitative detection of neonicotinoid insecticides (imidacloprid and thiamethoxam), animal growth promoter (β-adrenergic agonist zilpaterol), and flame retardant (polybrominated diphenyl ether 47). • Developed an automatic flow fluorescent biosensor system with parts-per-trillion detection sensitivity for the near real time detection of pesticide using a Kinetic Exclusion Assay (KinExA). • Measured antibody binding kinetics (Kd, kon, koff) using… Show more • Developed sensitive immunoassays for quantitative detection of neonicotinoid insecticides (imidacloprid and thiamethoxam), animal growth promoter (β-adrenergic agonist zilpaterol), and flame retardant (polybrominated diphenyl ether 47). • Developed an automatic flow fluorescent biosensor system with parts-per-trillion detection sensitivity for the near real time detection of pesticide using a Kinetic Exclusion Assay (KinExA). • Measured antibody binding kinetics (Kd, kon, koff) using the KinExA. • Established hybridoma cell lines for the production of monoclonal antibodies. Show less



National Plant Quarantine Service, Ministry of Agriculture

• Plant Inspection Official

  • Jan 1998 - Aug 1999

  Busan, Korea • Developed analytical methods for pesticide detection in imported plants using GC and HPLC